At IMKASID 2025 in Seoul, Samsung Bioepis shared how switching 🔁 to biosimilars can unlock major cost savings across Europe. Our findings highlight biosimilars’ potential to realize significant economic benefits for payers and patients alike, propelling us toward a more sustainable healthcare ecosystem. ➡️https://lnkd.in/gdBVwe8f #Biosimilars #InnovatingAccess #PassionForHealth
